Evidence map›Paper›PMID 24866147›Full record

ArticleHypertension (Dallas, Tex. : 1979)2014

Prostaglandin E-prostanoid4 receptor mediates angiotensin II-induced (pro)renin receptor expression in the rat renal medulla.

Fei Wang, Xiaohan Lu, Kexin Peng, Yaomin Du, Shu-Feng Zhou, Aihua Zhang, Tianxin Yang

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hypertension (Dallas, Tex. : 1979), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 72 citations in OpenAlex.

  1. Article
  2. Review
  3. Collecting duct renin regulates potassium homeostasis in mice.Acta physiologica (Oxford, England) · 2023
    Article
  4. Bioactive lipids in hypertension.Advances in pharmacology (San Diego, Calif.) · 2023
    Article
  5. Review
  6. Article
  7. Therapeutic potential ofFrontiers in pharmacology · 2023
    Article
  8. Review
  9. Article
  10. NaHypertension (Dallas, Tex. : 1979) · 2022
    Article
  11. Role of (pro)renin receptor in cyclosporin A-induced nephropathy.American journal of physiology. Renal physiology · 2022
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Fei WangFrom the Institute of Hypertension, Sun Yat-sen University School of Medicine, Guangzhou, China (F.W., X.L., K.P., T.Y.); Department of Internal Medicine, University of Utah, Salt Lake City (F.W., X.L., T.Y.); Veterans Affairs Medical Center, Salt Lake City, UT (F.W., X.L., T.Y.); Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China (Y.D.); Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa (S.-F.Z.); and Department of Nephrology, Nanjing Children's Hospital, Affiliated to Nanjing Medical University, Nanjing, China (A.Z.).
Xiaohan LuFrom the Institute of Hypertension, Sun Yat-sen University School of Medicine, Guangzhou, China (F.W., X.L., K.P., T.Y.); Department of Internal Medicine, University of Utah, Salt Lake City (F.W., X.L., T.Y.); Veterans Affairs Medical Center, Salt Lake City, UT (F.W., X.L., T.Y.); Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China (Y.D.); Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa (S.-F.Z.); and Department of Nephrology, Nanjing Children's Hospital, Affiliated to Nanjing Medical University, Nanjing, China (A.Z.).
Kexin PengFrom the Institute of Hypertension, Sun Yat-sen University School of Medicine, Guangzhou, China (F.W., X.L., K.P., T.Y.); Department of Internal Medicine, University of Utah, Salt Lake City (F.W., X.L., T.Y.); Veterans Affairs Medical Center, Salt Lake City, UT (F.W., X.L., T.Y.); Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China (Y.D.); Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa (S.-F.Z.); and Department of Nephrology, Nanjing Children's Hospital, Affiliated to Nanjing Medical University, Nanjing, China (A.Z.).
Yaomin DuFrom the Institute of Hypertension, Sun Yat-sen University School of Medicine, Guangzhou, China (F.W., X.L., K.P., T.Y.); Department of Internal Medicine, University of Utah, Salt Lake City (F.W., X.L., T.Y.); Veterans Affairs Medical Center, Salt Lake City, UT (F.W., X.L., T.Y.); Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China (Y.D.); Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa (S.-F.Z.); and Department of Nephrology, Nanjing Children's Hospital, Affiliated to Nanjing Medical University, Nanjing, China (A.Z.).
Shu-Feng ZhouFrom the Institute of Hypertension, Sun Yat-sen University School of Medicine, Guangzhou, China (F.W., X.L., K.P., T.Y.); Department of Internal Medicine, University of Utah, Salt Lake City (F.W., X.L., T.Y.); Veterans Affairs Medical Center, Salt Lake City, UT (F.W., X.L., T.Y.); Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China (Y.D.); Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa (S.-F.Z.); and Department of Nephrology, Nanjing Children's Hospital, Affiliated to Nanjing Medical University, Nanjing, China (A.Z.).
Aihua ZhangFrom the Institute of Hypertension, Sun Yat-sen University School of Medicine, Guangzhou, China (F.W., X.L., K.P., T.Y.); Department of Internal Medicine, University of Utah, Salt Lake City (F.W., X.L., T.Y.); Veterans Affairs Medical Center, Salt Lake City, UT (F.W., X.L., T.Y.); Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China (Y.D.); Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa (S.-F.Z.); and Department of Nephrology, Nanjing Children's Hospital, Affiliated to Nanjing Medical University, Nanjing, China (A.Z.).
Tianxin YangFrom the Institute of Hypertension, Sun Yat-sen University School of Medicine, Guangzhou, China (F.W., X.L., K.P., T.Y.); Department of Internal Medicine, University of Utah, Salt Lake City (F.W., X.L., T.Y.); Veterans Affairs Medical Center, Salt Lake City, UT (F.W., X.L., T.Y.); Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China (Y.D.); Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa (S.-F.Z.); and Department of Nephrology, Nanjing Children's Hospital, Affiliated to Nanjing Medical University, Nanjing, China (A.Z.). Tianxin.Yang@hsc.utah.edu.
Guangdong Provincial People's Hospital · CNUniversity of South Florida · USGuangdong Academy of Medical Sciences · CNUniversity of Utah · USVeterans Health Administration · US

Funding

Interaction of PGE2 and intrarenal RAS in AngII-induced hypertensionR01DK104072 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI YANG, TIANXIN · 2015 to 2025
$3.7M
Control of collecting duct function by lipid-derived factors in obesityR01DK094956 · NIDDK · UNIVERSITY OF UTAH · PI YANG, TIANXIN · 2013 to 2017
$1.6M
mPGES-1/EP1 in volume regulationI01BX001034 · VA · VA SALT LAKE CITY HEALTHCARE SYSTEM · PI YANG, TIANXIN · 2011 to 2014
–
BLRD VA I01 BX001034NIDDK NIH HHS DK094956NIDDK NIH HHS R01 DK094956NIDDK NIH HHS R01 DK104072
6 · The paper itself

Abstract

Angiotensin II (Ang II) stimulates (pro)renin receptor (PRR) expression in the renal collecting duct, triggering the local renin response in the distal nephron. Our recent study provided evidence for involvement of cyclooxygenase-2-prostaglandin E2 pathway in Ang II-dependent stimulation of PRR expression in the collecting duct. Here, we tested the role of E-prostanoid (EP) subtypes acting downstream of cyclooxygenase-2 in this phenomenon. In primary rat inner medullary collecting duct cells, Ang II treatment for 12 hours induced a 1.8-fold increase in the full-length PRR protein expression. To assess the contribution of EP receptor, the cell was pretreated with specific EP receptor antagonists: SC-51382 (for EP1), L-798106 (for EP3), L-161982 (for EP4), and ONO-AE3-208 (ONO, a structurally distinct EP4 antagonist). The upregulation of PRR expression by Ang II was consistently abolished by L-161982 and ONO and partially suppressed by SC-51382 but was unaffected by L-798106. The PRR expression was also significantly elevated by the EP4 agonist CAY10598 in the absence of Ang II. Sprague-Dawley rats were subsequently infused for 1 or 2 weeks with vehicle, Ang II alone, or in combination with ONO. Ang II infusion induced parallel increases in renal medullary PRR protein and renal medullary and urinary renin activity and total renin content, all of which were blunted by ONO. Both tail cuff plethysmography and telemetry demonstrated attenuation of Ang II hypertension by ONO. Overall, these results have established a crucial role of the EP4 receptor in mediating the upregulation of renal medullary PRR expression and renin activity during Ang II hypertension.

Indexed as

Angiotensin IIAnimalsCells, CulturedKidney MedullaMaleProrenin ReceptorRatsRats, Sprague-DawleyReceptors, Cell SurfaceReceptors, ProstaglandinReceptors, Prostaglandin E, EP4 SubtypeRenin-Angiotensin SystemAngiotensin IIProrenin ReceptorReceptors, Cell SurfaceReceptors, ProstaglandinReceptors, Prostaglandin E, EP4 Subtypedinoprostone

Identifiers

PMID24866147
PMCPMC4445967
OpenAlexW2142099499

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.